Presence of Chronic Kidney Disease Worsens Clinical Outcomes in Hf Patients Hospitalized With Covıd-19

Creative Commons License

Murat B., Murat S.

6. INTERNATIONAL HIPPOCRATES CONGRESS ON MEDİCAL AND HEALTH SCIENCES, Ankara, Türkiye, 30 Nisan - 01 Mayıs 2021, sa.1, ss.364-365

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Ankara
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.364-365



Coronavirus disease 2019 (COVID-19) is a novel and highly transmissable disease which has affected

millions of people worldwide. COVID-19 patients with multiple comorbidities including heart failure

(HF) show poor clinical outcomes. However, little is known about the effects of chronic kidney

disease(CKD) on clinical outcomes in HF patients with COVID-19. So, we aimed to evaluate the effect of

concomitant CKD on clinical outcomes in patients with HF who were hospitalized for COVID-19.


In this study, we retrospectively evaluated 240 consecutive patients hospitalized for COVID-19 who

had a previous diagnosis of HF with reduced or preserved ejection fraction in two centers, between March

15, 2020 and December 01, 2020. The diagnosis of HF was determined by searching for ICD-10: I50,

I50.1, I50.2, I50.9 in all available in-/outpatient hospital data. We compared clinical features, laboratory

findings and in-hospital outcomes according to estimated glomerular filtration rate (eGFR). Patients with

eGFR≥60 mL/min/1.73 m2 were determined as high eGFR group, and patients with eGFR<60

mL/min/1.73 m2 as low eGFR group. In-hospital clinical outcomes were defined as all-cause death,

respiratory failure requiring mechanical ventilation cardiogenic shock, length of intensive care unit (ICU)

stay and length of hospital stay.


Mean age of the study population was 73.2±10 years old and 67.5 % were male. One hundred and

fifty-two patients (63.3%) had an eGFR less than 60 mL/min/1.73 m2. There was no significant difference

between the two groups in terms of comorbidities include hypertension, diabetes, coronary artery disease

(p>0.05, for all). In the low eGFR group, the infection markers were significantly higher and the

haemoglobin value was also significantly lower (Table 1). Compared with patients with high eGFR, those

with low eGFR experienced longer length of intensive care unit (ICU) stay (4.0 days vs. 0.0 days;

p=0.003). Furthermore, clinical outcomes such as death, respiratory failure requiring mechanical

ventilation cardiogenic shock were worse in the low eGFR group.


This retrospective study of hospitalized patients with COVID-19 with HF showed that the presence of

low eGFR is associated with long ICU stay and worse clinical outcomes and laboratory parameters.